{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000036","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-05-14T20:05:05+00:00","discovered_at":"2026-05-14T20:06:00.351807+00:00","generated_at":"2026-05-14T20:06:17.138075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway","bullets":["Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.","R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.","Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.","SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.","Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000036","json":"https://secwatch.observer/filing/0001708599-26-000036.json","markdown":"https://secwatch.observer/filing/0001708599-26-000036.md","text":"https://secwatch.observer/filing/0001708599-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/0001708599-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/ser-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:06:17.138075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfd8da137751bc077b8b783c27a24388b5ad13cc","claim":"Serina Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $6.9 million, EPS $(0.58) per basic and diluted share.","evidence_excerpt":"Serina Therapeutics, Inc. (\"Serina\" or the \"Company\") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/0001708599-26-000036-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$6.9 million"},{"label":"EPS","value":"$(0.58) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}